Alemtuzumab: evidence for its potential in relapsing–remitting multiple sclerosis
J William L Brown, Alasdair J ColesDepartment of Clinical Neurosciences, University of Cambridge, Cambridge, UKAbstract: Alemtuzumab (previously known as Campath®) is a humanized monoclonal antibody directed against the CD52 antigen on mature lymphocytes that results in lymphopenia and s...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Dove Medical Press
2013-03-01
|
| Series: | Drug Design, Development and Therapy |
| Online Access: | http://www.dovepress.com/alemtuzumab-evidence-for-its-potential-in-relapsingndashremitting-mult-a12379 |